Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging
Due to spatial tumor heterogeneity and consecutive sampling errors, it is critically important to assess treatment response following antiangiogenic therapy in three dimensions as two-dimensional assessment has been shown to substantially over- and underestimate treatment response. In this study, we evaluated whether three-dimensional (3D) dynamic contrast-enhanced ultrasound (DCE-US) imaging allows assessing early changes in tumor perfusion following antiangiogenic treatment (bevacizumab administered at a dose of 10 mg/kg b.w.), and whether these changes could predict treatment response in colon cancer tumors that either are responsive (LS174T tumors) or none responsive (CT26) to the proposed treatment. Our results showed that the perfusion parameters of 3D DCE-US including peak enhancement (PE) and area under curve (AUC) significantly decreased by up to 69 and 77%, respectively, in LS174T tumors within 1 day after antiangiogenic treatment (P = 0.005), but not in CT26 tumors (P > 0.05). Similarly, the percentage area of neovasculature significantly decreased in treated versus control LS174T tumors (P < 0.001), but not in treated versus control CT26 tumors (P = 0.796). Early decrease in both PE and AUC by 45-50% was predictive of treatment response in 100% (95% CI 69.2, 100%) of responding tumors, and in 100% (95% CI 88.4, 100%) and 86.7% (95% CI 69.3, 96.2%), respectively, of nonresponding tumors. In conclusion, 3D DCE-US provides clinically relevant information on the variability of tumor response to antiangiogenic therapy and may be further developed as biomarker for predicting treatment outcomes.
基金：
NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 CA155289, R01 CA195443]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区外周血管病
最新[2023]版：
大类|1 区医学
小类|2 区外周血管病
第一作者：
第一作者机构：[1]Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford, 300 Pasteur Dr,Room H1307, Stanford, CA 94305 USA;[2]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Ultrasound,Canc Ctr, Guangzhou, Guangdong, Peoples R China;
通讯作者：
通讯机构：[1]Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford, 300 Pasteur Dr,Room H1307, Stanford, CA 94305 USA;
推荐引用方式(GB/T 7714)：
Zhou Jianhua,Zhang Huiping,Wang Huaijun,et al.Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging[J].ANGIOGENESIS.2017,20(4):547-555.doi:10.1007/s10456-017-9566-5.
APA：
Zhou, Jianhua,Zhang, Huiping,Wang, Huaijun,Lutz, Amelie M.,El Kaffas, Ahmed...&Willmann, Jurgen K..(2017).Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging.ANGIOGENESIS,20,(4)
MLA：
Zhou, Jianhua,et al."Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging".ANGIOGENESIS 20..4(2017):547-555
